Page 36 - ரோச் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ரோச். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ரோச் Today - Breaking & Trending Today

Roche's antibody cocktail for Covid rolls out in India - The Hindu BusinessLine


Roche’s antibody cocktail for Covid rolls out in India
May 24, 2021
Price to a patient, including tax, is ₹59,750
Doctors treating Covid-19 patients will now also have the antibody cocktail – Casirivimab and Imdevimab – for treatment. The first batch of the injectable from Swiss drugmaker Roche has been imported to India from the US, and the second batch is expected by mid-June. Cipla will market the product in India.
Global attention
The antibody cocktail received much global attention last year after former US President Trump was given the drugwhen he had contracted Covid.
A total of one lakh packs are slated for India, but each pack can treat two patients, said the company. The price to a patient is ₹59,750, inclusive of taxes, said the company, with the two-dose pack costing ₹119,500. ....

Bruno Jolain , V Simpson Emmanuel , European Union , Roche Pharma , Managing Director , Chief Executive Officer , Business Line , Medical Director , வ் சிம்ப்சன் இம்மானுவேல் , ஐரோப்பிய தொழிற்சங்கம் , ரோச் பார்மா , நிர்வகித்தல் இயக்குனர் , தலைமை நிர்வாகி அதிகாரி , வணிக வரி , மருத்துவ இயக்குனர் ,

Covid-19: Roche Antibody cocktail used to treat Trump launched in India at Rs 59,750/dose | India News


Roche s antibody cocktail drug will be available through leading hospitals and Covid treatment centers.
NEW DELHI: Drug major Roche India on Monday announced the launch of its first batch of antibody cocktail against Coronavirus in India. The antibody cocktail (Casirivimab and Imdevimab)is priced at Rs 59,750 per dose and will be marketed by Cipla in the country.
The Roche s antibody cocktail was given to then US President Donald Trump when he contracted the coronavirus disease in October last year.
The first batch of the antibody cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients, Cipla and Roche said in a joint statement. ....

Donald Trump , Roche India , Ndia News , Ndia News Today , Oday News , Google News , Reaking News , Roche Antibody Cocktail , Covid 19 , Covid Antibody Cocktail , Antibody Cocktail , டொனால்ட் துருப்பு , ரோச் இந்தியா , ஆன்டிபாடி காக்டெய்ல் ,

ASCO: Roche's Tecentriq grabs I-O's first win in post-surgery lung cancer, but it's limited—and an FDA approval could be, too


May 19, 2021 5:00pm
Roche s Tecentriq cut the risk of post-surgery cancer recurrence or death by 34% against best supportive care in patients with PD-L1-postivie stage II to IIIA non-small cell lung cancer. (Roche)
In early cancer that’s amenable to surgery, a field viewed as the next battleground for PD-1/L1 immunotherapies, Roche’s Tecentriq has claimed the first win in non-small cell lung cancer. But the drug’s role, at least in some patients, remains unclear.
Tecentriq slashed the risk of cancer recurrence or death after surgery by 34% in a study slated for the virtual American Society of Clinical Oncology meeting next month but only in patients with stage II to IIIA disease whose tumors bore the PD-L1 biomarker. ....

United States , Bill Anderson , Roche Genentech , Peter Welford , Charles Fuchs , Roche Tecentriq , American Society Of Clinical Oncology , European Medicines Agency , American Society , Clinical Oncology , Asco 2021 , Non Small Cell Lung Cancer , ஒன்றுபட்டது மாநிலங்களில் , ர சி து ஆண்டர்சன் , ரோச் ஜெநிஂடெக் , பீட்டர் வெல்ஃபோர்ட் , சார்லஸ் ஃப்யூக்ஸ் , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் , அமெரிக்கன் சமூகம் , மருத்துவ புற்றுநோயியல் ,

Roche receives FDA authorisation for testing of asymptomatic people with the cobas SARS-CoV-2 Test to help control the spread of COVID-19


Roche receives FDA authorisation for testing of asymptomatic people with the cobas SARS-CoV-2 Test to help control the spread of COVID-19

The high-throughput, highly sensitive cobas SARS-CoV-2 Test under FDA Emergency Use Authorisation can now be used to test individual or pooled samples from people without symptoms or other reasons to suspect COVID-19

Accurate, reliable and early detection of SARS-CoV-2 in potentially exposed individuals can help limit the spread of disease
PLEASANTON, Calif., May 18, 2021 /PRNewswire/ Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its
cobas SARS-CoV-2 Test for use on the widely available, high-throughput
cobas 6800/8800 Systems has received Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA) for testing individuals without symptoms or reasons to suspect COVID-19. This authorisation supports the guidance update from the U.S. Centers for Disease Control and Prevention ....

United States , Mike Weist , Elizabeth Baxter , Cindy Perettie , Centers For Disease , Us Centers For Disease , Head Of Molecular Lab , World Health Organization , Drug Administration , Roche Diagnostics Solutions , Clinical Laboratory Improvement Amendments , Roche Group , Pharmaceuticals Industry , Drug Administration Emergency Use Authorization , Use Authorisation , Emergency Use Authorisation , Disease Control , Molecular Lab , Roche Diagnostics , Middle East Respiratory Syndrome , Severe Acute Respiratory Syndrome , Emergency Use Authorization , Emergency Use , World Health Organization Model Lists , Essential Medicines , Dow Jones Sustainability Indices ,